Keyword: Japan

Takeda CEO Christophe Weber and Nissan's now-fallen chairman Carlos Ghosn have much more in common than their French nationality.

Sun Pharma is picking up two manufacturing plants and a portfolio of dermatology drugs in Japan for just $1 million.

The deal follows a flurry of consumer deals and comes as J&J's beauty products have been delivering strong growth, thanks in part to Ci:z.

The FDA slapped Japanese API maker Yuki Gosei Kogyo with a warning letter for failing to report lab testing data on released lots.

Officials in Japan have moved to swiftly cut the price on two top-selling cancer meds.

Shionogi's Roche-partnered Xofluza, a one-time, single-dose regimen, probably won't win U.S. approval till next winter.

An API maker in Bizen, Japan, has joined a growing list of Japanese drugmakers to be criticized by the FDA in warning letters and bans.

Takeda offloaded cancer assets, AstraZeneca formed drug discovery JV in China, Biocon's Herceptin biosimilar plant cleared FDA.

Dr. Reddy's recalls more meds in the U.S., while the EMA recanted its plant's GMP certificate; China approved a domestic Ebola vaccine.